

Why reduced folates are becoming more important than ever

Reduced folates have supported critical therapies for decades, particularly in oncology and other specialised therapeutic areas

Today, new clinical opportunities, including the recent US approval of a new therapeutic application for Leucovorin in Cerebral Folate Deficiency (CFD), are expanding their relevance and driving increased global demand. As the market evolves, ensuring adequate manufacturing capacity and supply continuity has become more important than ever.

More than 50 years of experience

As one of the world's leading manufacturers of reduced folates, Cerbios-Pharma SA, part of HAS Group, has been supporting pharmaceutical partners for more than 50 years. Reduced folates represent a core business area and a strategic focus for the company, backed by decades of manufacturing expertise, technological know-how, and regulatory excellence.

Over the years, Cerbios has built a strong reputation as a trusted global supplier of this important class of active pharmaceutical ingredients, establishing a leading supply position across all major regulated

markets, including Europe, the United States, Japan and, lastly, China.

Meeting growing global demand

The importance of reduced folates continues to grow as new therapeutic applications emerge. A key milestone occurred in March, 2026, with the approval of a new therapeutic application for Leucovorin in Cerebral Folate Deficiency (CFD) in the US. Ongoing research and the development of novel clinical applications continue to broaden the therapeutic potential of these molecules beyond their historical indications, recognising a wider range of biological activities and creating new opportunities for growth in both established and emerging markets. To support this increasing demand, Cerbios recently completed a major investment project aimed at expanding its manufacturing capabilities for reduced folates and strengthening long-term supply continuity.

Swissmedic approves expanded production unit

On 15 September, 2026, HAS Group announced that Swissmedic had approved Cerbios' expanded


production unit dedicated to the manufacture of reduced folates.

The approval marks an important milestone in HAS Group's long-term strategy to strengthen manufacturing capacity for this important API segment. The expansion has been designed to increase production capacity while improving operational flexibility and supply chain resilience, ensuring Cerbios can continue to meet the evolving needs of pharmaceutical customers worldwide. Swissmedic's approval now enables Cerbios to begin the qualification and validation activities required for the progressive introduction of the new manufacturing capacity. The additional capacity is expected to become available to customers by the beginning of 2027.

Investing in long-term supply continuity

The expanded production unit represents the first step in a broader plan aimed at further strengthening HAS Group's manufacturing footprint and supporting future growth in the reduced folates market.

*"The approval of this expanded production unit represents an important milestone for Cerbios and for the entire HAS Group," said **Waldo Mossi**, CEO of HAS Group. "Reduced folates have been at the heart of Cerbios' expertise for decades and this investment demonstrates our long-term commitment to supporting customers and*



patients through increased capacity, quality and supply reliability."

This achievement further reinforces HAS Group's commitment to ensuring long-term supply continuity while supporting both established therapeutic applications and future clinical opportunities involving reduced folates.

As part of the Group's broader growth strategy, additional investments are already planned to further strengthen HAS Group's manufacturing network and support the evolving needs of the global pharmaceutical market. This would also include additional capacity for folates, which the company will soon disclose details.

A strategic focus for HAS Group

The expansion also reflects the strategic importance of portfolio products, particularly reduced folates, within HAS Group.

Established in 2025 through the acquisition of Cerbios-Pharma SA, HAS Group combines advanced chemical and biological expertise to support customers through highly specialised CDMO services spanning APIs, HPAPIs, linker-payloads and Antibody-Drug Conjugates (ADCs).

Leveraging Cerbios' long-standing expertise and the broader capabilities of HAS Group, the company is uniquely positioned to support pharmaceutical innovators through an integrated development and manufacturing platform.

Reduced folates remain a strategically important portfolio class and a cornerstone of Cerbios' heritage, reflecting decades of commercial manufacturing leadership in this field.

In addition to supporting growing market demand, these investments reinforce the Group's commitment to unlocking the expanding therapeutic potential of these molecules and supporting their long-term development.

Building on this strong foundation, HAS Group also continues to invest in the expansion of its integrated CDMO platform, enhancing technological capabilities, fostering innovation and creating long-term value for customers across its entire offering.



**VALENTINO
MANDELLI**
Senior Manager Sales
HAS Group